GMAB, is a biotechnology company known for its innovative antibody therapeutics. Established in 1999 and based in Copenhagen, ...

Equities research analysts at William Blair issued their FY2029 earnings per share (EPS) estimates for shares of Genmab A/S ...

Genmab wisely chose not to pursue GEN3014 further, focusing instead on its existing pipeline projects. Click here to read an ...

Assetmark Inc. lowered its position in Genmab A/S (NASDAQ:GMAB – Free Report) by 78.1% during the fourth quarter, Holdings ...

Harbour BioMed created Élancé Therapeutics to develop bispecific antibody drugs for weight loss. Elsewhere, Geron’s CEO is ...

Barclays analyst Emily Field maintained a Buy rating on Genmab A/S (0MGB – Research Report) today and set a price target of DKK2,100.00. The ...

Fintel reports that on March 11, 2025, William Blair upgraded their outlook for Genmab A (NasdaqGS:GMAB) from Market Perform ...

Genmab A/S has a trailing 12 month Price to Earnings (P/E) ratio of 11.6 while the S&P 500 average is 29.3 Its forward ...

Stocks in the Nordic region declined Tuesday, with the OMX Nordic 40 Index declining 2.2%. Genmab A/S posted the largest decline among large stocks during the session, declining 9.2%, followed by ...

RBC Capital analyst Alistair Campbell lowered the firm’s price target on Genmab (GMAB) to DKK 2,300 from DKK 2,400 and keeps an Outperform ...

Genmab (GMAB) announced that Johnson & Johnson (JNJ) has decided that it will not exercise its option to receive a worldwide license to develop, manufacture and commercialize HexaBody-CD38. “While the ...

Danish cancer specialist Genmab’s stock took a hit after US healthcare giant Johnson & Johnson opted not to license its ...